- Home
- LSB vs RLMD Comparison
LSB vs RLMD Comparison
Compare LSB & RLMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LSB
- RLMD
- Stock Information
- Founded
- LSB 2002
- RLMD 2004
- Country
- LSB China
- RLMD United States
- Employees
- LSB N/A
- RLMD N/A
- Industry
- LSB
- RLMD Biotechnology: Pharmaceutical Preparations
- Sector
- LSB
- RLMD Health Care
- Exchange
- LSB NYSE
- RLMD Nasdaq
- Market Cap
- LSB 22.3M
- RLMD 22.0M
- IPO Year
- LSB N/A
- RLMD N/A
- Fundamental
- Price
- LSB $1.00
- RLMD $0.82
- Analyst Decision
- LSB
- RLMD Hold
- Analyst Count
- LSB 0
- RLMD 4
- Target Price
- LSB N/A
- RLMD $4.25
- AVG Volume (30 Days)
- LSB 13.8K
- RLMD 838.4K
- Earning Date
- LSB 06-21-2025
- RLMD 05-12-2025
- Dividend Yield
- LSB N/A
- RLMD N/A
- EPS Growth
- LSB N/A
- RLMD N/A
- EPS
- LSB N/A
- RLMD N/A
- Revenue
- LSB $79,415,311.00
- RLMD N/A
- Revenue This Year
- LSB $39.33
- RLMD N/A
- Revenue Next Year
- LSB $75.61
- RLMD N/A
- P/E Ratio
- LSB N/A
- RLMD N/A
- Revenue Growth
- LSB N/A
- RLMD N/A
- 52 Week Low
- LSB $0.36
- RLMD $0.24
- 52 Week High
- LSB $6.82
- RLMD $4.47
- Technical
- Relative Strength Index (RSI)
- LSB 30.09
- RLMD 71.69
- Support Level
- LSB $0.99
- RLMD $0.65
- Resistance Level
- LSB $1.09
- RLMD $0.77
- Average True Range (ATR)
- LSB 0.07
- RLMD 0.10
- MACD
- LSB 0.02
- RLMD 0.02
- Stochastic Oscillator
- LSB 27.81
- RLMD 88.60
About LSB LAKESHORE BIOPHARMA CO LTD
LakeShore Biopharma Co Ltd is a biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious diseases and cancer. It has developed a proprietary PIKA immunomodulating technology platform and a new generation of preventive and therapeutic biologics targeting Rabies, Coronavirus, Hepatitis B, Influenza, Shingles, and other virus infections. The company operates in China, the United States, Singapore, and the Philippines.
About RLMD Relmada Therapeutics Inc.
Relmada Therapeutics Inc is a clinical-stage biotechnology company. It is engaged in developing chemical entities with novel versions of drug products that address areas of high unmet medical need in the treatment of central nervous system diseases. The company is focused on the development of esmethadone (d-methadone, dextromethadone, REL-1017), an N-methyl-D-aspartate (NMDA) receptor antagonist. Its lead product candidate, esmethadone, is an oral agent for the treatment of depression and other potential indications.